Jazz Pharma Plc (JAZZ) Stock Price, Quote & News

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to tre...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 634 7800

Website: www.jazzpharma.com

Address:

Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland

Makingmillions192 Apr. 7 at 12:33 PM

$LEXX The stock is currently locked in a high-stakes battle between a technical breakout and a desperate short attack. Technical Breakdown • Daily Chart: We’ve cleared the 100-day SMA ($0.81). And the 200-day SMA ($0.88). This level, once a ceiling, is now firm support. The MACD shows a bullish expansion, while the RSI (75-80) sits in the power zone, typical of high-momentum runs. • Weekly Chart: The long-term & V-Bottom is nearly complete. Clearing $1.10 opens a resistance void up to $1.50–$1.70. • The Squeeze: With 373k shares short and a 1.5-day cover ratio, any positive news will force a violent covering rally. Shorts are trying to break the $1.00 psychological floor, but the trend is firmly bullish. With the April 30th MTA deadline looming and the cap table leaner after the Bunka gift, the risk is heavily skewed to the upside. The tape doesn’t lie 📈 $LLY $JAZZ $TEVA

0 · Reply

SilverEagle Apr. 6 at 8:01 PM

$JAZZ shorts gonna be crying uncle here soon. Slap that bass

0 · Reply

Quantumup Apr. 6 at 12:14 PM

RBC Capital⬆️ $NUVB's PT to $20 from $13 and reiterated at an Outperform rating. $JAZZ Servier DAWN MRK KZIA TNGX ERAS CMRX Here's what RBC Capital had to say in its note to investors: https://x.com/Quantumup1/status/2041126796435882351?s=20

0 · Reply

MikiTrader Apr. 2 at 8:00 AM

$JAZZ I’m not even sure if “pressure” really exists, but anyway, the company just seems to have way too much money. Even if it goes down, it would probably be limited… that’s what I think.

0 · Reply

Makingmillions192 Mar. 31 at 11:26 AM

$LEXX The odds of a major deal are high, supported by concrete strategic signals. Chris Bunka’s gift of 100k shares back to the treasury is a classic "cap table cleanup" to reduce dilution for an acquirer. More importantly, the April 30th MTA deadline with a global "PharmaCO" marks a critical expiration for exclusive data review. Hiring Richard Christopher—who was the CFO at DUSA during its sale to Sun Pharma—suggests Lexaria has moved from "R&D mode" to "Exit mode." With human data showing DehydraTECH turns GLP-1 injections into highly effective pills, Lexaria is no longer just a biotech; it's a "must-have" delivery platform for Big Pharma’s $100B+ weight-loss race. $LLY $JAZZ $TEVA $NVO

0 · Reply

Makingmillions192 Mar. 30 at 4:35 PM

$LEXX The Current Short Data (March 2026): • Short Interest: Approximately 373,000 shares are currently shorted (about 1.6% of the float). • The "Days to Cover": It would take roughly 2.3 to 3.7 days of average volume for all shorters to buy back their shares. This is a critical "squeeze" window; if a major catalyst hits, they will all be fighting for the same small exit door. • Off-Exchange/Dark Pool Ratio: Recently as high as 20–30%. This suggests significant "hidden" activity where big players try to suppress price action without moving the needle on the public tape. Institutional Stance: • UBS Group AG recently increased their position by over 4,900%. • Vanguard and Geode maintain stable, significant long positions. • Insiders (including the CEO) have been net buyers over the last 12 months. Tell-tale signs & catalysts: • M&A Cleanup (Share Gifts) • Massive Institutional Buys (UBS) • 24-Hour GLP-1 Dominance • April 30th Deal Deadline $UBS $LLY $JAZZ

1 · Reply

RenkoTradingSystem Mar. 29 at 2:59 PM

$JAZZ Weekly Chart No Market Permission yet on the SPY Weekly Candlestick Chart RSI to go long, however, a good time to create a watch list. $SPY $QQQ

0 · Reply

Makingmillions192 Mar. 27 at 2:23 PM

$JAZZ $LEXX $LLY $NVO $VKTX Potential Buyout Scenarios: • The "Emisphere" Ceiling ($1.8B): If valued as a top-tier delivery platform like the tech behind Rybelsus, a buyout could reach $72/share. This would turn Bunka’s gift into a $7M "sacrifice" for a $40M personal win. • The "Strategic Exit" ($230M-$500M): Matching Christopher’s previous $230M deal with Sun Pharma yields ~$9.20/share. A $500M deal hits $20/share. In both cases, the gift "cleans the tracks" to secure an 800%+ gain from current prices. • The "Cleanup" Logic: Gifting 100k shares to the treasury lowers acquisition costs for a buyer and minimizes shareholder dilution. It’s a "vote of confidence" that a massive payout is imminent.

0 · Reply

Makingmillions192 Mar. 27 at 2:17 PM

$LEXX In my opinion - Lexaria is currently in a high-stakes "pre-deal" phase that mirrors the final minutes of a championship game. • The M&A Specialist: CEO Richard Christopher previously led a company to a $230M buyout by Sun Pharma. His contract includes a specific "Material Transaction Bonus" for a change of control—he is literally paid to sell the company. • The Smoking Gun: On March 24, they confirmed active talks with several multinational pharmaceutical companies. Putting pressure on the existing MTA partner to license or acquire the platform. • This week, they announced 5 new patents protecting their tech until 2044, locking out competitors for 20 years. • The Chairman recently gifted 100k shares back to the company—a classic move to "clean the books" before a buyout. Lexaria has spent months removing every barrier to a deal. With multiple bidders at the table and an April 30th clock ticking, the "One-Yard Line" theory is stronger than ever. $LLY $NVO $VKTX $JAZZ

1 · Reply

StockConsultant Mar. 25 at 10:48 PM

$JAZZ Jazz Pharmaceuticals stock, nice day off support, watch for a top of range breakout at https://stockconsultant.com/?JAZZ

0 · Reply

Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference

Mar 24, 2026, 1:49 PM EDT - 13 days ago

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

Mar 18, 2026, 7:44 AM EDT - 20 days ago

Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026

Mar 12, 2026, 5:28 PM EDT - 25 days ago

Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential

Feb 24, 2026, 4:05 PM EST - 5 weeks ago

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

Feb 17, 2026, 4:15 PM EST - 6 weeks ago

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 10, 2026, 4:15 PM EST - 7 weeks ago

Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

Jan 12, 2026, 7:05 AM EST - 3 months ago

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Jan 8, 2026, 4:05 PM EST - 3 months ago

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Jan 6, 2026, 1:32 PM EST - 3 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit

Dec 17, 2025, 4:15 PM EST - 3 months ago

Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Dec 5, 2025, 9:00 AM EST - 4 months ago

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting

Dec 5, 2025, 7:12 AM EST - 4 months ago

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

Dec 2, 2025, 4:05 PM EST - 4 months ago

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium

Nov 18, 2025, 4:15 PM EST - 4 months ago

Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 17, 2025, 12:09 PM EST - 5 months ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

ZYME

Nov 17, 2025, 8:10 AM EST - 5 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

ZYME

Nov 17, 2025, 6:00 AM EST - 5 months ago

Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom

Nov 11, 2025, 7:45 AM EST - 5 months ago

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

Nov 5, 2025, 4:05 PM EST - 5 months ago

Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Oct 28, 2025, 4:05 PM EDT - 5 months ago

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Oct 22, 2025, 4:15 PM EDT - 5 months ago

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

Oct 21, 2025, 7:00 AM EDT - 6 months ago

Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer

Oct 17, 2025, 1:47 PM EDT - 6 months ago

3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street

AEHR TZOO

Oct 2, 2025, 6:37 PM EDT - 6 months ago

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Oct 2, 2025, 3:37 PM EDT - 6 months ago

US FDA approves Jazz Pharma's therapy for lung cancer

Sep 22, 2025, 7:45 AM EDT - 7 months ago

Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

Sep 9, 2025, 7:45 AM EDT - 7 months ago

Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

Aug 21, 2025, 4:15 PM EDT - 8 months ago

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 4:15 PM EDT - 8 months ago

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

Aug 20, 2025, 7:30 AM EDT - 8 months ago

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Aug 6, 2025, 3:07 PM EDT - 8 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Aug 6, 2025, 3:00 PM EDT - 8 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jul 22, 2025, 4:15 PM EDT - 9 months ago

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Jul 10, 2025, 7:30 AM EDT - 9 months ago

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Jul 7, 2025, 10:05 AM EDT - 9 months ago

Is JAZZ Stock Undervalued At $110?

Jul 1, 2025, 8:31 AM EDT - 10 months ago

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jun 10, 2025, 7:05 AM EDT - 10 months ago

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jun 9, 2025, 6:00 PM EDT - 10 months ago

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jun 2, 2025, 4:05 PM EDT - 11 months ago

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jun 2, 2025, 12:35 PM EDT - 11 months ago

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

May 29, 2025, 7:30 AM EDT - 11 months ago

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 21, 2025, 4:30 PM EDT - 11 months ago

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 6, 2025, 4:05 PM EDT - 11 months ago

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Apr 30, 2025, 4:15 PM EDT - 1 year ago

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Apr 25, 2025, 11:27 AM EDT - 1 year ago

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Apr 23, 2025, 4:15 PM EDT - 1 year ago

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Apr 22, 2025, 4:15 PM EDT - 1 year ago

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Makingmillions192 Apr. 7 at 12:33 PM

0 · Reply

SilverEagle Apr. 6 at 8:01 PM

$JAZZ shorts gonna be crying uncle here soon. Slap that bass

0 · Reply

Quantumup Apr. 6 at 12:14 PM

0 · Reply

MikiTrader Apr. 2 at 8:00 AM

$JAZZ I’m not even sure if “pressure” really exists, but anyway, the company just seems to have way too much money. Even if it goes down, it would probably be limited… that’s what I think.

0 · Reply

Makingmillions192 Mar. 31 at 11:26 AM

0 · Reply

Makingmillions192 Mar. 30 at 4:35 PM

1 · Reply

RenkoTradingSystem Mar. 29 at 2:59 PM

$JAZZ Weekly Chart No Market Permission yet on the SPY Weekly Candlestick Chart RSI to go long, however, a good time to create a watch list. $SPY $QQQ

0 · Reply

Makingmillions192 Mar. 27 at 2:23 PM

0 · Reply

Makingmillions192 Mar. 27 at 2:17 PM

1 · Reply

StockConsultant Mar. 25 at 10:48 PM

$JAZZ Jazz Pharmaceuticals stock, nice day off support, watch for a top of range breakout at https://stockconsultant.com/?JAZZ

0 · Reply

Doozio Mar. 25 at 2:21 PM

Thursday 🐑 2mro then walk into the weekend with da $BAND playing that $JAZZ like it’s 🐒🍌🧠⏰♾️

0 · Reply

Doozio Mar. 25 at 1:26 AM

$JAZZ if only they gave a sign first before da huckleberries go thru da $$$$

0 · Reply

NorthStarStats Mar. 25 at 1:20 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $HPE Score 97, $TWST Score 95, $EXE Score 68, $GLW Score 65, $JAZZ Score 60

0 · Reply

TradeTracs Mar. 24 at 7:50 PM

This ones giving me $LLY vibez on the monthly view. Here we have $JAZZ daily, with a snippet of its weekly. -Tight post earnings base with drying volume -Weekly just peaked above a triple inside candle stack -Digested November earnings & gave almost nothing back -Riding 5ema weekly to a T💎 Lets see how this one goes📈 (PS: yes it may breakout, but what we're looking for here is accompanied VOL surge for proper confirmation)

0 · Reply

Makingmillions192 Mar. 24 at 7:21 PM

$LEXX The trend is your friend and we have powerful bullish signals from the daily, weekly, and monthly candles. All of them are suggesting we are now in an up trend. Multinational Talks: Lexaria transitioned from "searching" to "negotiating," explicitly confirming active discussions with several multinational pharmaceutical companies. The April 30th Deadline: The MTA expiration, Eli Lilly’s oral approval, and Sun’s generic rollout all converge next month. Lexaria is the key to this "once-in-a-lifetime" window. $LLY $NVO $JAZZ $TEVA

0 · Reply

Makingmillions192 Mar. 24 at 2:30 PM

$LEXX Could see a large volume breakout anytime and prices soar. The writing is on the wall… $SUNPHARMA.NSE $JAZZ $TEVA

0 · Reply

Night_Owl_Biotech Mar. 24 at 2:31 AM

Attached is an updated calendar that documents the history of commercial-stage oncology focused M&A, showing the month & year of when the transaction was announced. It appears visually apparent that March to May is generally an active time of the year for M&A in this peer group. There's been 2-3 deals announced during this period we're in right now over the last 3 years. Day One proved no exception. If history is any guide, there will be 1 or 2 more before the end of May. Our educated guesses continue to be; $$IOVA $URGN $AUTL $ZYME via $JAZZ (even though ZYME does not sell a product we consider them commercial-stage). SNDX continues to be our #1 holding & most likely eventual M&A exit candidate. An INCY buyout could happen at any time. However, if a SNDX exit has not happened by now we suspect they are waiting for something we cannot think of. Watch us get the announcement tomorrow. This is not investment advice. This is for entertainment purposes only.

6 · Reply

WallStBandit Mar. 21 at 1:37 PM

$JAZZ waiting for next pr

0 · Reply

erevnon Mar. 19 at 7:41 PM

Piper Sandler maintains Jazz Pharmaceuticals $JAZZ at Overweight and raises the price target from $219 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Makingmillions192 Mar. 18 at 4:29 PM

$LEXX And it would give $JAZZ the ability to expand into GLP-1… ⏰ 🧨🚀💰💸

1 · Reply

Makingmillions192 Mar. 18 at 2:14 PM

$LEXX $JAZZ Interesting… Gemini seems to think that a deal with Pfizer, Novartis, or Astra would be a partnership with upfront payments, milestones, royalties etc… But Gemini also thinks that a company like $JAZZ would seek to acquire Lexaria instead of partnering with them. But the holy grail for Lexaria is a Master Licensing Agreement, where a partner pays for the right to apply DehydraTECH to any molecule in their portfolio, not just CBD. Maybe that is why the business consultants were brought in. You don’t hire large global life science consultants unless you are in deal making mode. Whether that is licensing mode or acquisition mode I guess we will have to wait and see… Bring it home Rich & Chris!!! 💰

0 · Reply

Makingmillions192 Mar. 18 at 2:06 PM

$LEXX Lexaria’s DehydraTECH-CBD has shown exceptional promise in treating hypertension. Across four human clinical trials (HYPER-H21-1 to H21-4), it delivered rapid, sustained reductions in blood pressure with zero serious adverse events. The FDA has cleared an IND for a formal Phase 1b study. Top Potential Partners • Pfizer: A cardiovascular giant that could use DehydraTECH to revitalize its aging hypertension portfolio. $PFE • Novartis: Could integrate the tech with blockbusters like Entresto to improve onset and absorption.$NVS • AstraZeneca: Deeply invested in heart and renal health; fits their search for non-traditional oral solutions. $AZN • Jazz Pharmaceuticals: As the owners of Epidiolex, they are the logical home for a clinically validated CBD-based blood pressure treatment. $JAZZ

1 · Reply

Market Cap	11.51B
Revenue (ttm)	4.27B
Net Income (ttm)	-356.15M
EPS (ttm)	N/A
PE Ratio	43.99
Forward PE	9.12
Profit Margin	-8.35%
Debt to Equity Ratio	1.24

Volume	1,218,300
Avg Vol	929,380
Day's Range	N/A - N/A
Shares Out	61.56M
Stochastic %K	55%
Beta	0.23
Analysts	Strong Sell
Price Target	$225.33